1063733-41-4

Basic information

• Product Name: N-[(2,4-DIMETHOXYPHENYL)METHYL]-1,2,4-THIADIAZOL-5-AMINE
• Synonyms: N-[(2,4-DIMETHOXYPHENYL)METHYL]-1,2,4-THIADIAZOL-5-AMINE;N-(2,4-DiMethoxybenzyl)-1,2,4-thiadiazol-5-aMine;(2,4-Dimethoxy-benzyl)-[1,2,4]thiadiazol-5-yl-amine
• CAS NO: 1063733-41-4
• Molecular Formula: C₁₁H₁₃N₃O₂S
• Molecular Weight: 251.30482
• Mol File: 1063733-41-4.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: N-[(2,4-DIMETHOXYPHENYL)METHYL]-1,2,4-THIADIAZOL-5-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(2,4-DIMETHOXYPHENYL)METHYL]-1,2,4-THIADIAZOL-5-AMINE(1063733-41-4)
• EPA Substance Registry System: N-[(2,4-DIMETHOXYPHENYL)METHYL]-1,2,4-THIADIAZOL-5-AMINE(1063733-41-4)

Safety Data

• Hazardous Substances Data: 1063733-41-4(Hazardous Substances Data)

Usage

General Description

N-[(2,4-dimethoxyphenyl)methyl]-1,2,4-thiadiazol-5-amine is a chemical compound with the molecular formula C11H13N3O2S. It belongs to the group of thiadiazoles, which are heterocyclic compounds containing a ring structure with nitrogen and sulfur atoms. This particular compound is an amine derivative, meaning it contains an amino group (NH2) attached to the thiadiazole ring. The presence of the 2,4-dimethoxyphenylmethyl group in the molecular structure gives it potential pharmacological and biological activities. Thiadiazole derivatives have been studied for their potential applications in medicine, such as antimicrobial, antioxidant, and anticancer properties. Additionally, they may also exhibit anti-inflammatory and analgesic effects. This chemical compound has the potential for wide-ranging applications in pharmaceutical research and development.

Upstream product

• 613-45-6 2,4-Dimethoxybenzaldehyde 
• 7552-07-0 1,3,4-thiadiazol-5-amine 
• 56553-60-7 sodium tris(acetoxy)borohydride 

Downstream Products

• 1235406-41-3 3-cyano-N-[(2,4-dimethoxyphenyl)methyl]-4-fluoro-N-(1,2,4-thiadiazol-5-yl)benzene-1-sulfonamide 
• 1354917-73-9 3-cyano-N-(2,4-dimethoxybenzyl)-4-[(3-methoxyphenyl)thio]-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1354917-93-3 3-cyano-N-(2,4-dimethoxybenzyl)-4-[2-methoxy-4-(trifluoromethyl)benzyl]-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1354917-98-8 3-cyano-N-(2,4-dimethoxybenzyl)-4-[2-pyridazin-4-yl-4-(trifluoromethyl)benzyl]-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1354917-64-8 3-cyano-N-(2,4-dimethoxybenzyl)-4-[(2-methoxyphenyl)thio]-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1354917-72-8 3-cyano-N-(2,4-dimethoxybenzyl)-4-[(4-methoxyphenyl)thio]-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1354917-79-5 3-cyano-N-(2,4-dimethoxybenzyl)-4-{[2-pyridazin-4-yl-4-(trifluoromethyl)phenyl]thio}-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1354917-89-7 3-cyano-N-(2,4-dimethoxybenzyl)-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1354917-87-5 4-bromo-3-cyano-N-(2,4-dimethoxybenzyl)-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide 
• 1432515-02-0 (R)-N-(2,4-dimethoxybenzyl)-5-fluoro-3-(1-(2-iodophenyl)ethyl)-2-oxo-N-(1,2,4-thiadiazol-5-yl)-2,3-dihydrobenzo[d]oxazole-6-sulfonamide 
• 1432514-51-6 C₃₃H₃₅N₅O₈S₂ 
• 1432514-77-6 3-((3',4'-dihydro-1'H-spiro[[1,3]dioxolane-2,2'-naphthalen]-8'-yl)methyl)-N-(2,4-dimethoxybenzyl)-5-fluoro-2-oxo-N-(1,2,4-thiadiazol-5-yl)-2,3-dihydrobenzo[d]oxazole-6-sulfonamide 
• 1432514-88-9 tert-butyl 8-((6-(N-(2,4-dimethoxybenzyl)-N-(1,2,4-thiadiazol-5-yl)sulfamoyl)-5-fluoro-2-oxobenzo[d]oxazol-3(2H)-yl)methyl)-4-fluoro-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1432514-98-1 (R)-3-(1-(3-bromophenyl)ethyl)-N-(2,4-dimethoxybenzyl)-5-fluoro-2-oxo-N-(1,2,4-thiadiazol-5-yl)-2,3-dihydrobenzo[d]oxazole-6-sulfonamide 

Relevant articles and documents

Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7

A series of acidic diaryl ether heterocyclic sulfonamides that are potent and subtype selective NaV1.7 inhibitors is described. Optimization of early lead matter focused on removal of structural alerts, improving metabolic stability and reducing cytochrome P450 inhibition driven drug-drug interaction concerns to deliver the desired balance of preclinical in vitro properties. Concerns over nonmetabolic routes of clearance, variable clearance in preclinical species, and subsequent low confidence human pharmacokinetic predictions led to the decision to conduct a human microdose study to determine clinical pharmacokinetics. The design strategies and results from preclinical PK and clinical human microdose PK data are described leading to the discovery of the first subtype selective NaV1.7 inhibitor clinical candidate PF-05089771 (34) which binds to a site in the voltage sensing domain.

Sulfonamide compound as sodium channel blocker and application thereof

The invention provides a sulfonamide compound as a sodium channel blocker and an application of the sulfonamide compound, and the sulfonamide compound has dual inhibitory activity on Nav1.7 and Nav1.3 at the same time and can be used as a medicine for tre

Sulfonamide compound used as sodium channel blocker, and application thereof

The invention provides a sulfonamide compound used as a sodium channel blocker, and an application thereof. The sulfonamide compound has dual inhibitory activity on Nav1.7 and Nav1.3 at the same time,and can be used as a medicine for widely treating pains

DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS

Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and R1A to R4A are defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic